Free tool
FDA Approval Tracker
Last checked: Nov 20, 2026Latest source record: Aug 28, 2026Drugs@FDA last updated: Nov 18, 2026Methods & limitations
Matching approvals
25
2023 to 2026
Breakthrough
5
Accelerated
7
Priority review
13
Orphan
20
By year
NDAs and BLAs matching the filters.
- NDA
- BLA
View as table
| Year | NDA | BLA |
|---|---|---|
| 2023 | 5 | 5 |
| 2024 | 3 | 3 |
| 2025 | 4 | 1 |
| 2026 | 3 | 1 |
25 approvals
Newest first. Hover a badge for what it means.
- Mimrylo (Rusfertide Acetate) · Takeda Pharms AmAug 28, 2026
To treat erythrocytosis in adults with polycythemia vera
- Zenbexus (Iberdomide Hydrochloride) · Bristol Myers SquibbAug 13, 2026
To be used in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent
- Sarclisa Escena (Isatuximab-Irfc) · Sanofi-Aventis U.S. LLCJul 9, 2026
- Beqalzi (Sonrotoclax) · Beone Medicines USAMay 13, 2026Original approval · NDA 220711NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton's tyrosine kinase inhibitor
- Komzifti (Ziftomenib) · KuraNov 13, 2025
To treat adults with relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 mutation who have no satisfactory alternative treatment options
- Wayrilz (Rilzabrutinib) · Genzyme CorpAug 29, 2025
To treat persistent or chronic immune thrombocytopenia that has not sufficiently responded to immunoglobulins, anti-D therapy, or corticosteroids
- Lynozyfic (Linvoseltamab-Gcpt) · Rengeneron Pharmaceuticals, Inc.Jul 2, 2025
To treat relapsed or refractory multiple myeloma after at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti CD38 monoclonal antibody
- Qfitlia (Fitusiran Sodium) · Genzyme CorpMar 28, 2025
To prevent or reduce the frequency of bleeding episodes in hemophilia A or B
- Grafapex (Treosulfan) · MedexusJan 21, 2025
For use in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome
- Alhemo (Concizumab-Mtci) · Novo Nordisk INCDec 20, 2024
For routine prophylaxis to prevent bleeding episodes in hemophilia A and B
- Revuforj (Revumenib Citrate) · SyndaxNov 15, 2024
To treat relapsed or refractory acute leukemia
- Hympavzi (Marstacimab-Hncq) · Pfizer INCOct 11, 2024
To prevent or reduce bleeding episodes related to hemophilia A or B
- Ocrevus Zunovo (Ocrelizumab and Hyaluronidase-Ocsq) · Genentech INCSep 13, 2024Original approval · BLA 761371Approval letter
- Rytelo (Imetelstat Sodium) · GeronJun 6, 2024
To treat low- to intermediate-1 risk myelodysplastic syndromes
- Vafseo (Vadadustat) · AkebiaMar 27, 2024
To treat anemia due to chronic kidney disease
- Ryzneuta (Efbemalenograstim Alfa-Vuxw) · Evive BiotechnologyNov 16, 2023
To treat neutropenia
- Ojjaara (Momelotinib Dihydrochloride) · GlaxosmithklineSep 15, 2023
To treat intermediate or high-risk myelofibrosis in adults with anemia
- Aphexda (Motixafortide Acetate) · Ayrmid PharmaSep 8, 2023
To use with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma
- Elrexfio (Elranatamab) · Pfizer INCAug 14, 2023Original approval · BLA 761345NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy
- Talvey (Talquetamab-Tgvs) · Janssen BiotechAug 9, 2023Original approval · BLA 761342NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat adults with relapsed or refractory multiple myeloma who have received at least four prior therapies
- Vanflyta (Quizartinib Dihydrochloride) · Daiichi Sankyo INCJul 20, 2023
To use as part of a treatment regimen for newly diagnosed acute myeloid leukemia that meets certain criteria
- Columvi (Glofitamab-Gxbm) · Genentech INCJun 15, 2023
To treat diffuse large B-cell lymphoma, not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma after two or more lines of systemic therapy
- Epkinly (Epcoritamab-Bysp) · Genmab US, Inc.May 19, 2023
To treat relapsed or refractory diffuse large B-cell lymphoma (not otherwise specified) and high-grade B-cell lymphoma after two or more lines of systemic therapy
- Jesduvroq (Daprodustat) · GlaxosmithklineFeb 1, 2023
To treat anemia caused by chronic kidney disease for adults on dialysis for at least four months
- Jaypirca (Pirtobrutinib) · Loxo OncolJan 27, 2023
To treat relapsed or refractory mantle cell lymphoma in adults who have had at least two lines of systemic therapy, including a BTK inhibitor
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.